Over 30 generic manufacturers agree to make Pfizer COVID-19 pill Medicines Patent Pool (MPP) announced on Thursday that nearly three dozen companies signed agreements to manufacture the generic versions of the oral COVID-19 therapy developed by Pfizer.
The sublicence agreements follow a voluntary licensing agreement signed by MPP and Pfizer in November 2021 to serve medicines for countries home to about 53% of the global population, the United Nations-backed organization said.
The deals will enable over 95 low- and middle-income countries to access the treatment, a combination of protease inhibitor nirmatrelvir and older antiviral ritonavir.
Teva Pharmaceutical in Israel and Shanghai Fosun Pharmaceutical in China are also included among 35 generic drugmakers selected for the production.
Entradas
No hay comentarios:
Publicar un comentario